About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...

Veru Veru’s oral drug, enobosarm, targets the androgen hormones that play a role in body development and reproductive health.

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study ... 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage ...

Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's NOVOb.CO popular weight-loss and diabetes drugs, Wegovy and ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday. The update about the popular semaglutide injections ...

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key secondary endpoints ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Veru had a pre-IND meeting with the FDA Division ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular outcomes ...